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 27 
ABSTRACT  28 
 29 
Objectives 30 
To assess the impact of 5 or more cycles of neoadjuvant chemotherapy (NACT) and 31 
cytoreductive outcomes on overall survival (OS) in patients undergoing interval debulking 32 
surgery (IDS) for advanced ovarian cancer.  33 
Methods 34 
A retrospective review of patients receiving NACT followed by IDS between 2007-2017. 35 
Patients were analysed according to number of NACT cycles received: group 1 consisted of 36 
patients receiving ≤4 cycles and group 2 consisted of those receiving ≥5 cycles. Outcomes 37 
were stratified by cytoreductive outcome, surgical complexity, stage and chemotherapy 38 
exposure. 39 
Results 40 
231 patients in group 1 and 167 in group 2 were identified. In group 1, the OS for those 41 
achieving Complete(R0), Optimal<1cm(R1) and Suboptimal(R2) was 51.1, 36.1, and 34.3 42 
months respectively. Statistically significant differences in survival were seen in patients 43 
achieving R0vR2(p<0.019) but not in R0vR1(p=0.125) or R1vR2(p=0.358).  In group 2, the 44 
OS for those achieving R0, R1 and R2 was 53.0, 24.7, and 22.1 months respectively. 45 
Statistically significant differences were seen between R0vR1 and R0vR2 (p<0.00001) but 46 
not between R1vR2 (p=0.917). No difference in OS was seen between groups 1 and 2.  In 47 
patients achieving R1, there was a trend towards decreasing OS with increasing exposure to 48 
NACT from 36.1(95%CI 32.0-40.2)months with 3 cycles to 24.3(95%CI 14.4-34.2)months 49 
with ≥6 cycles. 50 
Conclusions 51 
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Surgery with utilisation of cytoreductive procedures to achieve complete clearance should be 52 
offered to all patients even after ≥5 cycles if R0 can be achieved. R1 cytoreduction has 53 
questionable value in those receiving ≤4 cycles and no value in those receiving ≥5 cycles.  54 
 55 
 56 
KEYWORDS 57 
Ovarian cancer; Survival; Surgery; Chemotherapy; Patient selection; Neo-adjuvant 58 
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INTRODUCTION 59 
Cancer of the fallopian tube, ovary or peritoneum (epithelial ovarian cancer) is the second 60 
most common and the most lethal gynaecological malignancy (1). The foundation for the 61 
modern management of this condition is the utilisation of surgery with the intention to 62 
remove all macroscopic disease (2-4) and platinum and taxane-based chemotherapy, either as 63 
treatment following surgery (adjuvant) or as treatment both before and after surgery (neo-64 
adjuvant, NACT). Since the publication of two randomised controlled trials demonstrating 65 
non-inferiority of NACT over primary surgery (5, 6) the rates of NACT usage have 66 
increased, in the US, overall to 22.6%(7) with some centres using NACT in up to 34% of 67 
stage 3c patients and 62% of stage 4 patients (8). Suggested indications for NACT include:  68 
stage 3c disease where the extent of surgery to achieve a satisfactory cytoreductive outcome 69 
based on imaging or laparoscopy is considered to excessive; stage 4 disease; where the 70 
patient performance status is insufficient to undertake the required debulking procedure; 71 
where surgical expertise for the required surgery is unavailable; and, in some centres, in the 72 
obese or elderly where extensive upper abdominal procedures appear necessary (9). 73 
Although cytoreduction outcomes have repeatedly been demonstrated to be a significant 74 
modifiable marker of survival (10-12), the survival gains from extensive surgery to achieve 75 
complete (R0) cytoreduction after NACT is poorly quantified. Both the aforementioned 76 
randomised studies into NACT demonstrate that compared to primary surgery, NACT 77 
achieves elevated R0 rates but, paradoxically, delivers comparable overall survival (OS) 78 
rates.  79 
Previous reviews of NACT cycles and OS have offered conflicting results (13-15). However, 80 
the use of four cycles does appear to be increasing in practice with such regimes being 81 
utilised in recent trials (16). Although comparatively less commonly used, the safety of six 82 
cycles has also been recognised (17). The impact of extended (five or more) cycles of NACT 83 
on survival, especially in association with modern cytoreductive targets, remains poorly 84 
described in the literature. As such there remains little information regarding the optimal 85 
NACT regime to use but the joint Society of Gynecologic Oncology and American Society of 86 
Clinical Oncology guidance (18) currently favours four or less cycles of platinum and taxane-87 
based chemotherapy based upon the methodology described in the EORTC (6) and CHORUS 88 
(5) studies (which utilised three cycles) and the ongoing JCOG0602 (19) study (which 89 
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utilised four cycles). Extending NACT to 6 cycles raises theoretical biological concerns (20) 90 
relating to the development of resistant clones which may or may not be removed with 91 
subsequent cytoreductive surgery. Additionally, one could expect that any residual tumour 92 
may not only have greater resistance to chemotherapy but is also likely to receive less 93 
adjuvant chemotherapy compared to patients treated with primary surgery or less NACT.    94 
The purpose of this study therefore was to assess the impact increasing numbers of cycles of 95 
NACT, and the associated cytoreductive outcomes, have upon OS in patients undergoing 96 
interval debulking surgery (IDS) for stage 3 or 4 epithelial ovarian, tubal or peritoneal cancer 97 
(advanced ovarian cancer, AOC).  98 
MATERIALS AND METHODS 99 
We reviewed all patients diagnosed with AOC between 16th August 2007 and 16th February 100 
2017. All patients were managed by subspecialty trained gynaecological oncologists at the 101 
Pan-Birmingham Gynaecological Cancer Centre (PBGCC), Birmingham, United Kingdom, 102 
which serves a population of 2.2 million people. All patients were discussed at the Centre 103 
multi-disciplinary team (MDT) meeting and prospectively recorded in an electronic database. 104 
Approval for this study was obtained from the hospital clinical effectiveness department.  105 
 106 
All consecutive patients diagnosed with histologically proven AOC were identified from the 107 
database. Women with suspected AOC underwent a standard previous described (21) 108 
diagnostic pathway. Following discussion at the MDT meeting, women either underwent: 109 
primary debulking surgery (PDS), 3-4 cycles carboplatin AUC 6 +/- paclitaxel 175mg/m2 110 
based NACT with an intention to consider IDS, or palliation alone. NACT was used in 111 
patients with: stage 4 disease; poor performance status (ECOG/WHO 3-4); obvious porta 112 
hepatis involvement on scan or extensive/irresectable upper abdominal disease; small bowel 113 
mesenteric or extensive serosal involvement on diagnostic laparoscopy; or large amount of 114 
ascites with a serum albumin of less than 30g/l. These criteria were originally developed from 115 
the EORTC trial protocol prior to August 2007 (Performance status, absence of 116 
contraindications to primary surgery) and were updated following the final results to include 117 
stage 4 disease patients (6). As early adopters of complete macroscopic clearance as the 118 
primary surgical aim, in patients in which this would be unlikely to be achieved (due to 119 
disease or patient factors) we would defer to treatment with NACT. An additional one cycle 120 
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was sometimes used to facilitate logistical issues around timing of surgery. An additional two 121 
or three cycles of NACT were used in patients with a poor response (static disease, persistent 122 
ascites) following the initial three cycles of NACT. Women not exposed to any surgery were 123 
those with: progressive disease despite NACT; worsening performance status; severe 124 
cardiovascular disease; and patient choice. The PBGCC was an early adopter of advanced 125 
upper abdominal surgical procedures in the UK with detailed surgical outcomes previously 126 
published (22, 23). All patients are offered adjuvant chemotherapy tailored to their pre-127 
operative chemotherapy exposure. All adjuvant chemotherapy was delivered via the 128 
intravenous route as intraperitoneal chemotherapy is not the standard of care for AOC in the 129 
United Kingdom. Definitive histology (histological sub-type and grade) is obtained following 130 
review by specialist gynaecological oncology histopathologists.  131 
For this study the patient cohort was divided into two groups prior to analysis. Group 1 132 
included all those who underwent the standard NACT regime of up to four cycles (Three 133 
standard cycles and those with an additional cycle due to scheduling issues). Group 2 134 
consisted of patients who received extended treatment with NACT (five or more cycles) due 135 
to patient or disease factors. Sub-group analysis by number of cycles received was 136 
additionally performed.    137 
Data Collection 138 
The following data items were collected: age at initial diagnosis; body mass index (BMI); 139 
FIGO stage; histological sub-type and grade; level of cytoreduction achieved (R0, R1 and R2 140 
(sub-optimal)); surgical complexity score (low, intermediate and high (24)); number of cycles 141 
of NACT chemotherapy; chemotherapy regime; and, adjuvant number of cycles of 142 
chemotherapy. 143 
Statistical analysis 144 
Categorical variables were compared with the chi-squared test and continuous variables were 145 
compared with the Kruskal-Wallis or Mann-Whitney U test depending on the distribution of 146 
data. All tests were two-sided and p-values of <0.05 was regarded as being statistically 147 
significant.  148 
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The Kaplan-Meier method was used to estimate survival with survival compared using the 149 
Log rank method. Variables were selected for inclusion in the multivariate analysis model if a 150 
significant (p<0.05) difference was identified on univariate analysis. Multivariate analysis 151 
was done using the log rank test if the proportional hazards (PH) assumption was met using 152 
IBM SPSS statistics version 20.  153 
 154 
 155 
RESULTS 156 
Between 16th August 2007 and 16th February 2017, 858 patients received treatment for AOC 157 
at the PBGCC.  Of these, 610 (71%) underwent cytoreductive surgery with 248 (29%) 158 
receiving chemotherapy or palliation alone. Of the patients who underwent cytoreductive 159 
surgery, 210 (35%) underwent PDS and 400 (65%) underwent IDS. Overall R0, R1 and R2 160 
outcomes were achieved in 64%, 14% and 21% respectively.  161 
Of the 400 patients who underwent IDS, two were excluded from the analysis due to 162 
insufficient data being available, hence our study sample consisted of 398 patients. Of these, 163 
231 (58.0%) patients were in group 1 (≤4 cycles) with 111 (48.1%) receiving standard 164 
treatment with three cycles of NACT and the remaining 120 (51.9%) receiving an additional 165 
cycle to facilitate timing of IDS.  Group 2 (≥5 cycles) consisted of the remaining 167 (42.0%) 166 
patients. 167 
The patient characteristics are summarised in Table 1.  Compared to patients in group 2, 168 
patients in group 1: had a higher proportion of primary peritoneal cancer (p = 0.03); achieved 169 
a higher rate of R0 cytoreduction (p = 0.0003) with a lower rate of R2 cytoreduction (p = 170 
0.003); received more complex surgery (p = 0.001); were more likely to receive paclitaxel in 171 
addition to carboplatin (p = <0.0001); were more likely to receive bevacizumab (p = 0.03); 172 
and received a higher median number of adjuvant chemotherapy cycles (p = 0.0001). 173 
The median OS of all patients treated with IDS was 40.1 (95%CI 35.8 – 44.4) months with 174 
OS in those achieving R0, R1 and R2 being 51.8 (95%CI 45.0 – 58.5), 29.5 (95%CI 22.2 – 175 
36.7) and 28.9 (95%CI 22.0 – 35.6) months respectively. A significant difference in OS was 176 
seen between those achieving R0 and R1 (p = 0.00005) and R0 and R2 (p = <0.000001) with 177 
no significant difference seen between R1 and R2 (p = 0.52). 178 
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Survival patterns differed between patients in group 1 and patients in group 2. Patients in 179 
group 1 had an OS of 44.3 (95%CI 37.0 – 51.5) months.  OS decreased from 51.1 (95%CI 180 
42.8 – 59.3) months in those who achieved R0 to 34.3 (95%CI 30.6 – 38.0) months in those 181 
who only achieved R2.  Patient who achieved R1 levels of cytoreduction had an OS of 36.1 182 
(95%CI 30.8 – 41.4).  The difference in OS between patients achieving R0 and R2 was 183 
significant (p = 0.019), but the differences in OS between patients achieving R0 and R1 and 184 
R1 and R2 were not (p=0.125 and p=0.358 respectively) (Figure 1A).  185 
Patients in group 2 had an OS of 36.5 (95%CI 28.7 – 44.2) months. OS for those achieving 186 
R0, R1 and R2 was 53.0 (95%CI 40.1 – 65.8), 24.7 (95%CI 17.8 – 31.6) and 22.1 (95%CI 187 
11.9 – 32.3) months respectively.  The difference in OS between patients achieving R0 and 188 
R1 was significant (p= <0.00001), as was the difference between patients achieving R0 and 189 
R2 (p=<0.00001). There was no significant difference in OS between patients achieving R1 190 
and R2 (p=0.917) (Figure 1B) 191 
There was no significant difference in the OS between groups 1 and 2 (44.3 (95%CI 37.0 – 192 
51.5) months v 36.5 (95%CI 28.7 – 44.2) months) (p>0.05) (Figure 2). On multivariate 193 
analysis, adjusting for cytoreductive outcome, stage of disease, and chemotherapy regime, the 194 
difference between R0 and R2 (p = 0.026) in group 1 and between R0 and R1 (p = <0.0001) 195 
and R0 and R2 (p = <0.00001) in group 2 remained significant (Table 2). 196 
The number of patients receiving ≤3, 4, 5 or ≥6 cycles of NACT was 111, 120, 46 and 121 197 
respectively. Subgroup analysis, looking at the actual number of cycles of NACT received, 198 
demonstrated that, for patients achieving R1 (n=55), OS decreased from 36.1 months (95% 199 
CI 32.0-40.2) in those receiving 3 cycles of NACT (n=8), to 24.3 months (95% CI 14.4-34.2) 200 
in patients receiving six or more cycles (n=20) (Table 3).  Although overall this was not a 201 
statistically significant decrease, the OS of patients receiving three cycles of NACT was 202 
significantly longer than patients receiving five cycles (p=0.017), as was the OS of patients 203 
receiving four cycles compared to five cycles (p=0.011).  No significant difference in OS was 204 
seen in those obtaining R0 or R2 irrespective of NACT exposure. 205 
In group 1, most (62.8%) patients received low complexity surgery. Only 16% of patients 206 
received high complexity surgery.  Although the OS in patients achieving R0 following high, 207 
intermediate and low complexity surgery was 39.6 (95%CI 21.9 – 57.3) months, 56.2 (95%CI 208 
40.5 – 71.9) months and 52.2 (95%CI 36.9 – 67.5) months respectively, the difference 209 
between the groups was not statistically significant. (Figure 3A)   210 
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Only nine (5.5%) patients in group 2 underwent high complexity surgery with patients more 211 
commonly receiving intermediate (23.8%) or low (70.7%) complexity surgery. No patients 212 
receiving high complexity surgery achieved R2 outcomes.  Although the OS in patients 213 
achieving R0 was 52.9 (95%CI 34.9 – 70.9) months with low complexity surgery, 56.0 214 
(95%CI 28.8 – 83.2) months with intermediate complexity surgery and 25.0 (95%CI 21.3 – 215 
28.7) months with high complexity surgery, the difference between these groups was not 216 
statistically significant (Figure 3B).  217 
 218 
DISCUSSION 219 
Our study finds that complete cytoreduction remains a significant independent marker of 220 
survival in patients undergoing cytoreductive surgery even after 5 cycles of NACT. 221 
Additionally, whether R0 is achieved with Low, Intermediate or High complexity surgery 222 
makes no significant difference to overall survival. Our findings furthermore demonstrate that 223 
R1 is not an acceptable cytoreductive target in patients receiving five or more cycles of 224 
chemotherapy and are suggestive of decreasing overall survival in patients obtaining R1 with 225 
increasing exposure to NACT. If complete cytoreduction in these patients is not possible, 226 
apart from for any palliative procedures, surgery should be abandoned in favour of 227 
continuation of chemotherapy alone.  228 
Whilst we acknowledge that these results may be influenced by patient selection our total 229 
cohort OS including PDS, IDS and non-operated cases has been shown to be comparable to 230 
international peers (21). Within this cohort, in those receiving PDS 65.2% achieved R0 and 231 
80.5% achieved R1 or better comparing well with other cohorts such as Chi (3) (27% and 232 
80%), EORTC PDS arm (6) (19.7% and 42.2%) and CHORUS PDS arm (5) (17% and 41%). 233 
NACT is used in conjunction with maximum effort cytoreductive surgery with corresponding 234 
elevated cytoreduction rates, 64% R0 and 77.9% R1 or better compared to EORTC NACT 235 
arm (46.9% and 73.9%) and CHORUS NACT arm (43% and 73%). 236 
This is, to our knowledge, the largest study examining the use of extended cycles of NACT in 237 
the treatment of AOC and It confirms previous findings that complete cytoreduction remains 238 
a significant marker of survival in AOC (10). As with previous studies (13, 14) no significant 239 
difference was seen in OS between those receiving four or less or five or more cycles. 240 
Patients can therefore be reassured that the addition of additional cycles of NACT, if logistics 241 
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interferes with organisation of theatre scheduling, does not adversely impact survival. 242 
Equally, patients selected for surgery after 6 cycles of NACT because of performance status 243 
or response rates can be reassured that surgery even at that stage confers survival benefit if 244 
complete is achieved 245 
Across our entire cohort we demonstrate no benefit from R1 cytoreduction in patients 246 
receiving IDS although our results may be significantly influenced by the large number of 247 
patients receiving more than our standard three cycles of NACT. On subgroup analysis, there 248 
may be a benefit in R1 cytoreduction in those receiving four or less cycles of NACT although 249 
this requires further investigation. Surgery after 5 cycles of NACT confers survival benefit 250 
only when complete cytoreduction is achieved. Where surgery results in residual disease even 251 
at R1 this survival advantage from surgery is lost. Although relatively few patients achieved 252 
R1 following IDS, there is a trend in this subgroup towards decreasing OS with increasing 253 
exposure to NACT. Such a finding would be consistent with the argument often asserted that 254 
PDS inhibits the development of resistant clones (25) whereas any residual disease remaining 255 
after IDS will, not only have a greater proportion of resistant clones, but also be less likely to 256 
receive as many cycles of adjuvant chemotherapy to eradicate it. As such this study supports 257 
the Goldie-Coldman hypothesis (20) of the pathogenesis of AOC.  258 
Irrespective of biological models of resistance however our study still demonstrated no 259 
significant difference in OS in those patients who obtained R0 between those in group 1 and 260 
group 2. Our results therefore contrast with a smaller study of 24 patients by Columbo (15) 261 
suggesting a significantly depressed OS in their patients receiving extended NACT compared 262 
to those receiving a standard regime. Although this could well be due to sample size there 263 
appeared to be certain differences in surgical ethos between the cohort described by Columbo 264 
and those treated at the PBGCC, but without complete denominator descriptors any 265 
comparison between the two groups is impossible (21). Our study is in agreement with Da 266 
Costa Miranda (17) who also examined extended treatment with NACT followed by surgery 267 
and found that highest OS was obtained in those obtaining R0 following NACT. The OS in 268 
that study was 41.9 months and we postulate that the slightly lower OS may be due to that 269 
study not giving adjuvant chemotherapy to those patients receiving IDS after 6 cycles.  (17). 270 
We postulate that there may be a survival benefit despite concerns about toxicity from some 271 
consolidation adjuvant chemotherapy (in our centre 2-3 cycles) even after extensive exposure 272 
to NACT. We suggest therefore that establishing the value of consolidation chemotherapy 273 
following IDS after extended NACT cycles is a trial worthy of consideration. 274 
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 275 
One of the limitations of our study is the lack of accurate initial disease distribution data. 276 
However, there was no significant difference in survival amongst patients who were 277 
completely cytoreduced following low, intermediate or high complexity surgery after 278 
extended treatment with NACT. As such, even in patients with more dispersed disease 279 
(implied by the required surgical effort to achieve complete cytoreduction), the OS appears to 280 
be not significantly different from those with a presumed lower tumour burden who were also 281 
completely cytoreduced. However, consistent with a study by Horowitz (26), patients 282 
receiving high complexity surgery (with a presumed greater tumour load), did have a lower 283 
median OS than those who underwent low or intermediate complexity surgery. These results 284 
may be due to the relatively small sample size included in our study. Further research is 285 
needed to ensure that there remains a true benefit from high complexity surgery in patients 286 
with large volume disease after extensive exposure to NACT. A second limitation is the 287 
proportion of women receiving an extra cycle of chemotherapy to time surgery, despite this 288 
our NACT regime still is consistent with previous studies and remains the largest piece of 289 
work in this space. Finally, the PBGCC does not, at present, utilise intra-peritoneal 290 
chemotherapy and as such our results may not be applicable to centres who have incorporated 291 
this into their NACT regime.   292 
Despite the development of personalised medicine in gynaecological oncology our use of 293 
NACT or PDS remains comparatively inflexible with no sophisticated mechanisms to predict 294 
outcomes. Our data does however offer the potential for a more patient tailored approach to 295 
primary treatment strategies.  It is possibly primary therapy in the form of surgery is best for 296 
some patients, NACT for others, with tailored NACT objectives to make surgery to RO 297 
achievable or improve the patients’ condition to render surgery safe. Such individualisation is 298 
likely in the future, though appropriate studies are necessary.  299 
The Joint Society of Gynecologic Oncology and American Society of Clinical Oncology 300 
guidance (18) on the use of NACT suggests utilising either three (based upon the findings of 301 
CHORUS/EORTC (5, 6)) or four cycles (pending the results of JCOG0602 (19)). Our data 302 
raises questions about the value of R1 cytoreduction in 4 or less cycles (and no value of R1 303 
cytoreduction following 5 or more cycles) and suggests that prior to the matured data from 304 
JCOG0602, three cycles of NACT should remain standard. Indeed, the suggestion that the OS 305 
benefit from R1 may be impaired by four compared to three cycles of NACT questions 306 
whether the use of an extra cycle of NACT to facilitate timing of surgery can be justified. 307 
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Despite concerns regarding the value of R1 cytoreduction in IDS, our data shows that if more 308 
than 4 cycles are needed for patient or disease factors it can be used with no adverse effects 309 
providing that R0 is achieved. 310 
 311 
CONCLUSION 312 
In conclusion, our data suggests that surgery should be offered to all patients irrespective of 313 
NACT exposure and performed if R0 can be achieved. R1 cytoreduction has no value in 314 
those receiving five or more cycles of NACT and thus should not be considered an acceptable 315 
cytoreductive outcome in this group. In patients receiving five or more cycles of NACT if 316 
complete cytoreduction in these patients is not possible, save for any palliative procedures, 317 
surgery should be abandoned in favour of continuation of chemotherapy alone. Further 318 
studies examining limited cycles of NACT to improve performance status and the impact of 319 
high complexity surgery in those receiving five or more cycles of NACT are strongly 320 
encouraged.  321 
 322 
 323 
 324 
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 409 
  Group 1 Group 2 p Total 
  n=231(%) n=167   n=398 
Age 
63.0 95%CI (41.1-
84.9) 
65.1 95%CI (44.0- 
86.3) >0.05 
63.9 95%CI (42.2 - 
85.6) 
BMI 26 IQR 23-29 25 IQR 21-29 >0.05 25 IQR 22 - 29 
Site   
 
    
Ovary 142(61.5) 110(65.9) >0.05 252(63.3) 
Fallopian Tube 49(21.2) 41(24.6) >0.05 90(22.6) 
Primary Peritoneal 40(17.3) 16(9.6) 0.029 56(14.1) 
Histology   
 
    
Serous 218(94.4) 152(91.0) >0.05 370(93.0) 
MMMT 6(2.6) 6(3.6) >0.05 12(3.0) 
Clear cell 1(0.4) 1(0.6) >0.05 2(0.5) 
Mixed 3(1.3) 5(3.0) >0.05 8(2.0) 
Anaplastic/Undiffererentiated 0(0.0) 1(0.6) >0.05 1(0.3) 
Endometroid 1(0.4) 0(0.0) >0.05 1(0.3) 
Unknown 2(0.9) 2(1.2) >0.05 4(1.0) 
Grade   
 
    
1 7(3.0) 6(3.6) >0.05 13(3.3) 
2 1(0.4) 1(0.6) >0.05 2(0.5) 
3 219(94.8) 155(92.8) >0.05 374(94.0) 
Unknown 4(1.7) 5(3.0) >0.05 9(2.3) 
Stage   
 
    
3 153(66.2) 120(71.9) >0.05 273(68.6) 
4 78(33.8) 47(28.1) >0.05 125(31.4) 
Cytoreduction   
 
    
R0 165(71.4) 90(53.9) 0.00032 255(64.1) 
R1 27(11.7) 28(16.8) >0.05 55(13.8) 
R2 39(16.9) 49(29.3) 0.0031 88(22.1) 
Surgical Complexity   
 
    
LOW 0-3 145(62.8) 118(70.7) >0.05 263(66.1) 
INTER 4-7 49(21.2) 40(24.0) >0.05 89(22.4) 
HIGH 8+ 37(16.0) 9(5.4) 0.0011 46(11.6) 
Chemo therapy regime   
 
    
Carbo 26(11.3) 68(40.7) <0.0001 94(23.6) 
Carbo taxol 205(88.7) 99(59.3) <0.0001 304(76.4) 
Additional bevacizumab 19(8.2) 5(3.0) 0.031 24(6.0) 
Adjuvant cycles 3 IQR 3-4 2 IQR 2-3 <0.0001 3 IQR 2-3 
 
 
Table 1: Clinico-pathological-treatment data of all patients treated with four or less cycles of NACT 
and IDS (Group 1) and five or more cycles of NACT and IDS (Group 2) 
Table1
    Hazard Ratio 95% CI p 
 
 
 
 
 
 
 
G
ro
u
p 
1 Carbo taxol vrs Carbo  1.5495 0.928 - 2.588 >0.05 
R0 vrs R1 1.5723 0.928 - 2.664 >0.05 
R0 vrs R2 1.7709 1.069 - 2.933 0.0264 
R2 Vrs R1 0.8879 0.460 - 1.715 >0.05 
Stage 3 vrs Stage 4  1.6264 1.106 - 2.392 0.0134 
 
 
 
 
 
 
 
 
G
ro
u
p 
2 Carbo taxol vrs Carbo  1.1990 0.826 - 1.742 >0.05 
R0 vrs R1 2.7810 1.663 - 4.650 0.0001 
R0 vrs R2 2.6729 1.759 - 4.062 <0.00001 
R2 Vrs R1 1.0400 0.613 - 1.765 >0.05 
Stage 3 vrs Stage 4  0.7970 0.525 - 1.212 >0.05 
 
Table 2: Multivariate analysis of the effect of cytoreduction on OS in group 1 and group 2 
 
Table2
  
Cycles 
 
 
n 
R0 R1 R2 
OS (months) 
95% CI 
(months) OS (months) 
95% CI 
(months) OS (months) 
95% CI 
(months) 
≤3 111 50.0 36.3 - 63.7 36.1 32.0 - 40.2 34.3 26.4 - 42.2 
4 120 52.2 41.7 - 62.7 33.4 21.7 - 45.1 34.1 14.5 - 53.7 
5 46 50.9 5.6 - 96.2 26.6 22.6 - 30.6 46.1 15.9 - 76.3 
≥6 121 53.0 39.9 - 66.1 24.3 14.4 - 34.2 20.5 15.9 - 25.1 
 
Table 3: Median OS of all patients analysed by cytoreductive outcomes and NACT exposure. 
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Tables/Figures 
Table 1: Clinico-pathological-treatment data of all patients treated with four or less cycles of 
NACT and IDS (Group 1) and five or more cycles of NACT and IDS (Group 2) 
Figures 1: Kaplan-Meier curve of OS by cytoreductive outcome in Group 1 (A) and Group 2 
(B) patients undergoing treatment with NACT and IDS 
Figure 2: Kaplan-Meir curve of OS for patients in Group 1 and Group 2 undergoing treatment 
with IDS and NACT 
Table 2: Multivariate analysis of the effect of cytoreduction on OS in group 1 and group 2 
Table 3: Median OS of all patients analysed by cytoreductive outcomes and NACT exposure.  
Figure 3A & 3B: Kaplan-Meier curve comparing OS in patients achieving RO with Low, 
intermediate and high surgical complexity surgery in Group 1 (3A) and Group 2 (3B) 
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